Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial

IMPORTANCE: Patients selected to receive neoadjuvant chemotherapy (NAC) are usually those at higher risk of relapse, and there is a need to find better therapeutic options for these patients. OBJECTIVE: To determine the efficacy and safety outcomes for patients with hormone receptor (HR)–positive, E...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Miguel, Hegg, Roberto, Kim, Sung-Bae, Schenker, Michael, Grecea, Daniela, Garcia-Saenz, Jose Angel, Papazisis, Konstantinos, Ouyang, QuChang, Lacko, Aleksandra, Oksuzoglu, Berna, Reeves, James, Okera, Meena, Testa, Laura, Shimizu, Chikako, Denduluri, Neelima, Adamchuk, Hryhoriy, Dakhil, Shaker, Wei, Ran, Forrester, Tammy, Fernandez, Maria Munoz, Zimmermann, Annamaria, Headley, Desiree, Johnston, Stephen R. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164117/
https://www.ncbi.nlm.nih.gov/pubmed/35653145
http://dx.doi.org/10.1001/jamaoncol.2022.1488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164117/
https://www.ncbi.nlm.nih.gov/pubmed/35653145
http://dx.doi.org/10.1001/jamaoncol.2022.1488

Ejemplares similares